[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"avascular-necrosis-of-femur-head\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:avascular-necrosis-of-femur-head":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100600751","clinical-transformation-of-bone-reconstruction-with-autologous-bone-marrow-mesenchymal-stem-cells-in-vitro-to-repair-avascular-necrosis-of-femur-head-100600751",false,"NCT07101562","Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Avascular Necrosis of Femur Head","Inclusion Criteria:\n\n1. Capable of understanding and voluntarily signing the informed consent form before the study;\n2. Meets the diagnostic criteria in the \"Clinical Diagnosis and Treatment Guidelines for Adult Femoral Head Necrosis in China (2020)\";\n3. Age range: 20 - 65 years old (inclusive of boundary values), gender not restricted;\n4. Staged as ARCO II stage;\n5. Non-traumatic femoral head necrosis;\n6. Has received conservative treatment (such as physical therapy, blood-activating, analgesic drugs, etc.) for more than 2 weeks, and the target hip joint still shows persistent pain symptoms;\n7. The subjects are usually able to move, not bedridden or in a wheelchair for a long time, and can walk more than 50 meters without the help of crutches or walking sticks;\n8. During the trial period and within 90 days after the surgery, the subjects have no pregnancy plans and voluntarily take effective contraceptive measures.\n\nExclusion Criteria:\n\n1. Based on the researcher's judgment, the subjects had a history of trauma and the injury affected the target hip joint;\n2. In the six months prior to screening, there were obvious injuries involving the target hip joint;\n3. The subject's femoral head necrosis was due to other diseases affecting the hip joint (such as rheumatoid arthritis, psoriatic arthritis, gouty arthritis, symptomatic cartilage calcification, bone necrosis, active infection), or according to the researcher's judgment, peripheral or central nervous system lesions that might affect the assessment of pain and function of the target hip joint (such as back pain, knee joint disease, intervertebral disc protrusion, sciatic nerve pain, fibromyalgia, diabetic neuropathy, etc.);\n4. The femoral head of the target hip joint had obvious necrosis, collapse, joint fusion, etc.;\n5. Those who had a history of hip joint replacement, arthroplasty, or other hip joint surgeries, or planned to undergo surgical treatment of any lower limb\u002Fhip joint during the study period;\n6. The target hip joint had suppurative arthritis or a previous history;\n7. The target hip joint had obvious joint effusion;\n8. During the screening period, the target hip joint had active joint infection or skin ulceration, infection in the surgical area, or any significant chronic skin disease that might interfere with the surgical procedure;\n9. The subject was treating the target hip joint, and within 30 days before screening, had used opioids or glucocorticoids for treatment; or was required to use opioids or glucocorticoids for long-term treatment during the study period;\n10. Patients who had received any drug injection or surgical treatment in the hip joint (both sides or any one side) within 6 months before the treatment start;\n11. Started using drugs such as cilostazol for promoting blood circulation and anticoagulation therapy 8 weeks before screening;\n12. Note: If antihypertensive drugs or anticoagulant drugs such as cilostazol were used for treatment for ≥ 8 weeks before screening, they could be used at a stable dose during the study period;\n13. The subject had a disease requiring systemic glucocorticoid treatment;\n14. Abnormal liver and kidney function: At the time of screening, AST or ALT \\> 2 × upper limits of normal (ULN); or serum creatinine \\> 1.5 × ULN, or creatinine clearance rate ≤ 50 mL\u002Fmin;\n15. Note: For men, the creatinine clearance rate (mL\u002Fmin) = \\[(140 - age) × weight (kg)\\] \u002F \\[0.818 × Cr (μmol\u002FL)\\]; for women, the creatinine clearance rate (mL\u002Fmin) = male creatinine clearance rate (mL\u002Fmin) × 0.85;\n16. The subject had any type of active malignant tumor and was receiving systemic chemotherapy; or within 5 years before screening, was diagnosed with cancer (excluding squamous cell carcinoma or basal cell carcinoma of the skin);\n17. According to the researcher's judgment, before enrollment, 12-lead electrocardiogram (ECG) showed clinically significant abnormalities; including QTc (QTcB) \\> 450 ms, or heart rate \\> 100 bpm, or QRS \\> 120 ms, or PR \\> 220 ms;\n18. Basic cardiovascular diseases: Within 6 months before enrollment, had experienced the following cardiovascular events: myocardial infarction or coronary artery bypass surgery or traumatic coronary artery reperfusion surgery or stroke; unstable angina pectoris; variant angina pectoris; symptomatic congestive heart failure (New York Heart Association cardiac function grade III-IV or ejection fraction ≤ 35%);\n19. Uncontrolled hypertension (defined as systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg after standardized antihypertensive drug treatment);\n20. Positive hepatitis B surface antigen, hepatitis C antibody, AIDS antibody, syphilis antibody tests;\n21. Those who are known or suspected to be allergic to the active or inactive ingredients of the research drug;\n22. Gastrointestinal underlying diseases: having a history of gastrointestinal bleeding or perforation after using non-steroidal anti-inflammatory drugs (NSAIDs); subjects with active gastrointestinal ulcer bleeding within 30 days before enrollment, or who have had recurrent ulcer bleeding in the past;\n23. Allergic to the test drug or having a history of hypersensitivity reaction;\n24. Subjects unable to avoid non-habitual physical activities (such as starting new weightlifting exercises);\n25. Having a clear history of mental disorder, or having a history of abuse of psychotropic drugs or drug addiction;\n26. Alcohol (defined as drinking more than 2 units per day\u002F more than 14 units per week, 1 unit being equivalent to 360ml of beer or 45ml of 40% alcohol content spirits or 150ml of wine) or drug abusers; or those with mental disorders;\n27. Pregnant women, lactating women, and women of childbearing age who have not undergone sterilization surgery\u002Fare not in menopause\u002Fare unwilling to use medically approved effective contraceptive measures during the study period; men who have not undergone sterilization surgery\u002Fare unwilling to use medically approved effective contraceptive measures during the study period;\n28. Those who have participated in any other clinical trials within 3 months before screening;\n29. Other situations deemed unsuitable for participation in this trial by the investigator.","ALL","20 Years","65 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The commercial decalcified bone scaffold combined with the patient's autologous bone marrow mesenchymal stem cells was used for in vitro culture to form tissue-engineered bone, and the effect of this tissue-engineered bone in early non-traumatic femoral head necrosis was explored.",[26],"Avascular Necrosis of Femur Head","RECRUITING","2026-04-28",{"date":30,"type":31},"2026-05-04","ACTUAL",{"date":33,"type":20},"2026-04-20",{"date":35,"type":20},"2028-12",{"name":37,"class":38},"The First Affiliated Hospital of Xinxiang Medical College","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100600945","influence-of-antiseptic-washes-on-wound-healing-complications-after-tha-100600945","NCT07104084","Influence of Antiseptic Washes on Wound Healing Complications After THA","Comparison of Wound Healing Complications After Anterior Total Hip Arthroplasty Using Povidone-iodine or Chlorhexidine as Antiseptic Wash","Inclusion Criteria:\n\n* osteoarthritis or avascular necrosis of the femoral head, failed conservative management, indicated for total hip replacement\n\nExclusion Criteria:\n\n* reported or documented allergy to chlorhexidine or povidone-iodine","18 Years",{"count":49,"type":20},420,[23],"The purpose of this research trial is to evaluate the effect of two types of washing solutions on wound healing after total hip replacement surgery. Washing solutions are used routinely during total hip replacements to clean the wound after the components have been placed and the wound is about to be closed with sutures. It is currently not known which washing solution may be better for wound healing and whether a certain solution decreases the risk of wound healing complications after total hip replacement. Therefore, this research trial is being conducted.\n\nStudy participants will be randomized into one of two groups: washing the surgical wound with povidone-iodine solution (Surgiphor, Becton Dickinson, Franklin Lakes, NJ) or chlorhexidine solution (Irrisept, Irrimax Corporation, Lawrenceville, GA). All patients will undergo standard of care total hip replacements without any other change in surgery. The best type of solution that cleans the wound and potentially leads to better wound healing is unknown. This study will evaluate whether there is difference in surgical wound healing between the two washing solutions. The study will pay for the washing solutions. Patients will follow up for standard postoperative visits. At the 2-week and 6-week visits, pictures of the surgical incision will be taken and saved in the electronic medical record and evaluated in a standardized way for healing of the incision and the appearance of the scar. Postoperative complications and returns to the hospital or additional surgeries will be collected from the electronic medical record.",[53,26],"Hip Osteoarthritis","2026-02-03",{"date":56,"type":31},"2026-02-05",{"date":58,"type":31},"2025-10-09",{"date":60,"type":20},"2028-01-01",{"name":62,"class":38},"F. Johannes Plate",2,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":39},"100565329","multicentre-sms-study---fr-100565329","NCT06640764","Multicentre SMS Study - FR","Étude Prospective, Multicentrique, Non contrôlée, Non randomisée, Ouverte évaluant la Performance et la stabilité de l'Implant fémoral Non cimenté SMS","Inclusion Criteria:\n\n* Patient suffering from a severely painful and\u002For disabling hip joint due to osteoarthritis, traumatic arthritis, developmental dysplasia of the hip, or avascular necrosis of the femoral head, and requiring a total hip replacement.\n* Patient who will receive a Medacta SMS femoral stem.\n* Patient agrees to comply with the study requirements.\n* Patient has signed the consent form.\n* Patient is affiliated with a social security system.\n* Patient aged 18 to 75 years\n\nExclusion Criteria:\n\n* Participation in biomedical research.\n* Minor patient.\n* Protected adult patient.\n* Vulnerable individuals as defined by Article L1121-6 of the Public Health Code.\n* Pregnant or breastfeeding women.\n* Patient unable to express their non-opposition.\n* Patient refusing the collection of their personal data.\n* Acute, systemic, or chronic infection. Skeletal immaturity.\n* Grossly deformed anatomy (at the surgeon's discretion).\n* Osteomalacia for which the fixation of an uncemented implant is contraindicated.\n* Patient suffering from active rheumatoid arthritis or osteoporosis.\n* Patient with metabolic disorders likely to impair bone formation when the fixation of an uncemented implant is contraindicated.\n* Patient suffering from muscle atrophy or neuromuscular disease.\n* Patient with an allergy to the implant material.\n* Any patient who cannot or does not wish to give their informed consent to participate in the study.\n* Patient whose prospects of regaining independent mobility would be compromised by known coexisting medical problems.\n* Any contraindication mentioned in the instructions for use of the investigational medical device.","85 Years",{"count":73,"type":20},260,"OBSERVATIONAL","Prospective, multicentre, non controled, non randomised, clinical study to assess the performance and the stability of SMS femoral stem",[77,53,78,26],"Dysplasia of Hip Joint","Traumatic Arthritis of Hip","2024-10-11",{"date":81,"type":31},"2024-10-15",{"date":83,"type":31},"2024-09-01",{"date":85,"type":20},"2037-09-01",{"name":87,"class":88},"Medacta International SA","INDUSTRY"]